On Friday, November 26, biotechnology company Novavax stated that it has started working on the formulation of a new vaccine in view of the recent Omicron COVID variant detected in South Africa, reported CNN. The company has already begun developing a novel recombinant spike protein based on the known genetic sequence of B.1.1.529, and it will be available for testing and production in the …